doi: 10.1080/14737175.2025.2490539. Online ahead of print.
UK medical cannabis registry: an updated clinical outcomes analysis of patients with post-traumatic stress disorder
- PMID: 40235073
- DOI: 10.1080/14737175.2025.2490539
Abstract
Background: Cannabis-based medicinal products (CBMPs) are a potential treatment for post-traumatic stress disorder (PTSD), but their long-term efficacy and safety need further investigation. This study assessed the changes in health-related quality of life (HRQoL) and adverse events in PTSD patients prescribed CBMPs.
Research design and methods: This observational cohort study included PTSD patients enrolled on the UK Medical Cannabis Registry for 18 months or longer. Changes in PTSD-specific symptoms (IES-R), anxiety (GAD-7), sleep quality (SQS), and general HRQoL (EQ-5D-5 L) were assessed at 1, 3, 6, 12, and 18 months.
Results: In 269 patients, significant improvements in PTSD symptoms, anxiety, sleep quality, and HRQoL were observed at all follow-up points (p < 0.001). On multivariate logistic regression, male gender (OR = 0.51; 95% CI:0.28-0.94; p = 0.034) was associated with a reduced chance of reporting improvements in IES-R. Adverse events were reported by 70 (26.02%) patients, with insomnia (n = 42, 15.61%) and fatigue (n = 40, 14.87%) being the most common.
Conclusions: CBMPs were associated with improvements in PTSD symptoms, anxiety, sleep, and HRQoL at up to 18 months. Although the study’s observational nature limits causal conclusions, these findings support further assessment of medical cannabis.
Trial registration: This is an observational study and is not registered as a clinical trial.
Keywords: Anxiety; Cannabis; Post-traumatic stress disorder; Psychiatry; Sleep.
How Cannabis-Based Medicinal Products Are Transforming PTSD Treatment
Introduction to Cannabis-Based Medicinal Products for PTSD
Post-traumatic stress disorder (PTSD) is a complex mental health condition that can severely impact an individual’s life. Traditional treatments, such as therapy and medications, may not work for everyone. This is where Cannabis-Based Medicinal Products (CBMPs) come in. Studies increasingly show that CBMPs, particularly those containing tetrahydrocannabinol (THC), can provide significant relief for patients suffering from PTSD.
The Benefits of Cannabis-Based Medicinal Products (CBMPs) for PTSD
Recent research highlights the considerable benefits of Cannabis-Based Medicinal Products (CBMPs) in managing PTSD symptoms. Patients report reductions in anxiety, improvements in sleep quality, and better overall health-related quality of life (HRQoL). These improvements are not just short-term; they show promise in providing long-term relief with consistent use.
How CBMPs Work for PTSD Treatment
Cannabinoids, like THC, interact with the body’s endocannabinoid system, which helps regulate various physiological and psychological processes. For PTSD patients, this interaction can help modulate the stress response, reduce hyperarousal symptoms, and promote relaxation and sleep. The ability of CBMPs to address the root causes of PTSD makes them a promising treatment option.
Potential Benefits and Considerations of CBMPs
Cannabis-Based Medicinal Products (CBMPs) provide a range of therapeutic benefits, especially in managing PTSD, anxiety, and sleep disorders. While some patients may experience mild side effects, such as fatigue or insomnia, these are generally manageable and occur less frequently than with traditional psychiatric treatments. It’s important to recognize that psychoactive compounds like THC not only alleviate symptoms but also foster a sense of well-being; a therapeutic effect often overlooked. Many patients find this emotional and mental upliftment profoundly meaningful as part of their healing journey.
Furthermore, THC and other cannabinoids have shown potential in reducing opioid use, offering a solution to the growing opioid crisis. As more patients seek relief from chronic pain or PTSD, many have turned to opioids, leading to dependence and addiction. By offering an alternative that addresses pain and mental health issues without the addictive properties of opioids, CBMPs have emerged as a valuable tool in combating the opioid epidemic.
The positive effects of psychoactive cannabinoids are often overshadowed by misconceptions and political pressures. However, they play a vital role in promoting holistic wellness, offering effective relief with fewer harmful side effects compared to traditional medications.
Conclusion II: Exploring the Future of Cannabis in PTSD Treatment
In conclusion, Cannabis-Based Medicinal Products show great promise for long-term relief from PTSD symptoms. As with any treatment, patients should consult healthcare providers before starting any cannabis regimen. Ongoing research and clinical trials are essential to fully understand how CBMPs can be effectively integrated into PTSD management.
Revolutionary Research on the ECS, cannabinoids and cannabis-based medicine for healthcare from a trusted nonprofit.
